Cargando…
Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States
BACKGROUND: The prevalence of antimicrobial resistance among gram-negative pathogens in complicated intra-abdominal infections (cIAIs) has increased. In the absence of timely information on the infecting pathogens and their susceptibilities, local or regional epidemiology may guide initial empirical...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658949/ https://www.ncbi.nlm.nih.gov/pubmed/29090091 http://dx.doi.org/10.1186/s13756-017-0264-2 |
_version_ | 1783274082452635648 |
---|---|
author | Prabhu, Vimalanand S. Solomkin, Joseph S. Medic, Goran Foo, Jason Borse, Rebekah H. Kauf, Teresa Miller, Benjamin Sen, Shuvayu S. Basu, Anirban |
author_facet | Prabhu, Vimalanand S. Solomkin, Joseph S. Medic, Goran Foo, Jason Borse, Rebekah H. Kauf, Teresa Miller, Benjamin Sen, Shuvayu S. Basu, Anirban |
author_sort | Prabhu, Vimalanand S. |
collection | PubMed |
description | BACKGROUND: The prevalence of antimicrobial resistance among gram-negative pathogens in complicated intra-abdominal infections (cIAIs) has increased. In the absence of timely information on the infecting pathogens and their susceptibilities, local or regional epidemiology may guide initial empirical therapy and reduce treatment failure, length of stay and mortality. The objective of this study was to assess the cost-effectiveness of ceftolozane/tazobactam + metronidazole compared with piperacillin/tazobactam in the treatment of hospitalized US patients with cIAI at risk of infection with resistant pathogens. METHODS: We used a decision-analytic Monte Carlo simulation model to compare the costs and quality-adjusted life years (QALYs) of persons infected with nosocomial gram-negative cIAI treated empirically with either ceftolozane/tazobactam + metronidazole or piperacillin/tazobactam. Pathogen isolates were randomly drawn from the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS) database, a surveillance database of non-duplicate bacterial isolates collected from patients with cIAIs in medical centers in the USA from 2011 to 2013. Susceptibility to initial therapy was based on the measured susceptibilities reported in the PACTS database determined using standard broth micro-dilution methods as described by the Clinical and Laboratory Standards Institute (CLSI). RESULTS: Our model results, with baseline resistance levels from the PACTS database, indicated that ceftolozane/tazobactam + metronidazole dominated piperacillin/tazobactam, with lower costs ($44,226/patient vs. $44,811/patient respectively) and higher QALYs (12.85/patient vs. 12.70/patient, respectively). Ceftolozane/tazobactam + metronidazole remained the dominant choice in one-way and probabilistic sensitivity analyses. CONCLUSIONS: Based on surveillance data, ceftolozane/tazobactam is more likely to be an appropriate empiric therapy for cIAI in the US. Results from a decision-analytic simulation model indicate that use of ceftolozane/tazobactam + metronidazole would result in cost savings and improves QALYs, compared with piperacillin/tazobactam. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13756-017-0264-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5658949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56589492017-10-31 Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States Prabhu, Vimalanand S. Solomkin, Joseph S. Medic, Goran Foo, Jason Borse, Rebekah H. Kauf, Teresa Miller, Benjamin Sen, Shuvayu S. Basu, Anirban Antimicrob Resist Infect Control Research BACKGROUND: The prevalence of antimicrobial resistance among gram-negative pathogens in complicated intra-abdominal infections (cIAIs) has increased. In the absence of timely information on the infecting pathogens and their susceptibilities, local or regional epidemiology may guide initial empirical therapy and reduce treatment failure, length of stay and mortality. The objective of this study was to assess the cost-effectiveness of ceftolozane/tazobactam + metronidazole compared with piperacillin/tazobactam in the treatment of hospitalized US patients with cIAI at risk of infection with resistant pathogens. METHODS: We used a decision-analytic Monte Carlo simulation model to compare the costs and quality-adjusted life years (QALYs) of persons infected with nosocomial gram-negative cIAI treated empirically with either ceftolozane/tazobactam + metronidazole or piperacillin/tazobactam. Pathogen isolates were randomly drawn from the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS) database, a surveillance database of non-duplicate bacterial isolates collected from patients with cIAIs in medical centers in the USA from 2011 to 2013. Susceptibility to initial therapy was based on the measured susceptibilities reported in the PACTS database determined using standard broth micro-dilution methods as described by the Clinical and Laboratory Standards Institute (CLSI). RESULTS: Our model results, with baseline resistance levels from the PACTS database, indicated that ceftolozane/tazobactam + metronidazole dominated piperacillin/tazobactam, with lower costs ($44,226/patient vs. $44,811/patient respectively) and higher QALYs (12.85/patient vs. 12.70/patient, respectively). Ceftolozane/tazobactam + metronidazole remained the dominant choice in one-way and probabilistic sensitivity analyses. CONCLUSIONS: Based on surveillance data, ceftolozane/tazobactam is more likely to be an appropriate empiric therapy for cIAI in the US. Results from a decision-analytic simulation model indicate that use of ceftolozane/tazobactam + metronidazole would result in cost savings and improves QALYs, compared with piperacillin/tazobactam. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13756-017-0264-2) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-27 /pmc/articles/PMC5658949/ /pubmed/29090091 http://dx.doi.org/10.1186/s13756-017-0264-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Prabhu, Vimalanand S. Solomkin, Joseph S. Medic, Goran Foo, Jason Borse, Rebekah H. Kauf, Teresa Miller, Benjamin Sen, Shuvayu S. Basu, Anirban Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States |
title | Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States |
title_full | Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States |
title_fullStr | Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States |
title_full_unstemmed | Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States |
title_short | Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States |
title_sort | cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the united states |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658949/ https://www.ncbi.nlm.nih.gov/pubmed/29090091 http://dx.doi.org/10.1186/s13756-017-0264-2 |
work_keys_str_mv | AT prabhuvimalanands costeffectivenessofceftolozanetazobactamplusmetronidazoleversuspiperacillintazobactamasinitialempirictherapyforthetreatmentofcomplicatedintraabdominalinfectionsbasedonpathogendistributionsdrawnfromnationalsurveillancedataintheunitedstates AT solomkinjosephs costeffectivenessofceftolozanetazobactamplusmetronidazoleversuspiperacillintazobactamasinitialempirictherapyforthetreatmentofcomplicatedintraabdominalinfectionsbasedonpathogendistributionsdrawnfromnationalsurveillancedataintheunitedstates AT medicgoran costeffectivenessofceftolozanetazobactamplusmetronidazoleversuspiperacillintazobactamasinitialempirictherapyforthetreatmentofcomplicatedintraabdominalinfectionsbasedonpathogendistributionsdrawnfromnationalsurveillancedataintheunitedstates AT foojason costeffectivenessofceftolozanetazobactamplusmetronidazoleversuspiperacillintazobactamasinitialempirictherapyforthetreatmentofcomplicatedintraabdominalinfectionsbasedonpathogendistributionsdrawnfromnationalsurveillancedataintheunitedstates AT borserebekahh costeffectivenessofceftolozanetazobactamplusmetronidazoleversuspiperacillintazobactamasinitialempirictherapyforthetreatmentofcomplicatedintraabdominalinfectionsbasedonpathogendistributionsdrawnfromnationalsurveillancedataintheunitedstates AT kaufteresa costeffectivenessofceftolozanetazobactamplusmetronidazoleversuspiperacillintazobactamasinitialempirictherapyforthetreatmentofcomplicatedintraabdominalinfectionsbasedonpathogendistributionsdrawnfromnationalsurveillancedataintheunitedstates AT millerbenjamin costeffectivenessofceftolozanetazobactamplusmetronidazoleversuspiperacillintazobactamasinitialempirictherapyforthetreatmentofcomplicatedintraabdominalinfectionsbasedonpathogendistributionsdrawnfromnationalsurveillancedataintheunitedstates AT senshuvayus costeffectivenessofceftolozanetazobactamplusmetronidazoleversuspiperacillintazobactamasinitialempirictherapyforthetreatmentofcomplicatedintraabdominalinfectionsbasedonpathogendistributionsdrawnfromnationalsurveillancedataintheunitedstates AT basuanirban costeffectivenessofceftolozanetazobactamplusmetronidazoleversuspiperacillintazobactamasinitialempirictherapyforthetreatmentofcomplicatedintraabdominalinfectionsbasedonpathogendistributionsdrawnfromnationalsurveillancedataintheunitedstates |